Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease

Prior treatment

• Alcohol or drug abuse.
• Abdominal surgery in the last 6 months.
• Have previously received a drug with the same mechanism of action of the drug indicated by your doctor (anti-TNFα, anti-α4β7, anti-p40 or JAK inhibitor).
• Alcohol or drug abuse.

Other illness

• Having an immune-mediated disease other than IBD at the baseline visit.
• Having a neoplasm or an active infection at the time of the baseline visit.
• Active infection with hepatitis B, C or HIV virus.
• Advanced chronic disease or any other pathology that prevents the follow-up of the protocol of this study.
• Active infection with hepatitis B, C or HIV virus.

Age

• Under 18 years old.
• Under 18 years old.

Other

• Pregnancy or lactation.
• Ostomy.
• Colectomy in patients with UC.
• Indication of biologic treatment for a cause other than IBD.
• Indication of biologic treatment to prevent postoperative recurrence in CD.
• Refusal to give consent for participation in the study.
  • Group 2: patients without IBD
• Pregnancy or lactation.
• Finding of macroscopic alterations during the ileocolonoscopy, or finding of relevant inflammatory alterations in the biopsies obtained during the ileocolonoscopy.
• Refusal to give consent for participation in the study.

• Over 18 years.
• Diagnosis of IBD according to the criteria of the European Crohns and Colitis Organization (ECCO).
• Have indication of treatment with a biologic drug or tofacitinib.
• Be the first received drug with a given mechanism of action (anti-TNFα, anti-α4β7, anti-p40 or Janus kinase (JAK) inhibitor).
• Have endoscopic activity of IBD within 1 month of starting the biologic treatment (see definitions section: SES-CD ≥ 3 in CD and endoscopic sub-index of May ≥ 2 in UC).
• In the case of CD, receive the biologic treatment by luminal activity (not perianal).
• \- Patients not diagnosed with IBD, or other inflammatory, allergic, malignant or autoimmune diseases, where a ileocolonoscopy is performed due to the normal clinical practice.

Criteria the registry did not label

• Group 1: Patients with IBD